Corporate News Blog – Aralez Announced District Court Decision to Uphold VIMOVO Patents

LONDON, UK / ACCESSWIRE / June 29, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=ARLZ. The Company announced on June 27, 2017, that the United States District Court for the District of New Jersey upheld the validity of two patents owned by a subsidiary of Aralez and licensed to Horizon Pharma PLC, over VIMOVO (naproxen/esomeprazole magnesium). The dispute arose over the case that Dr. Reddy’s, Lupin, or Mylan would infringe at least one of the two patents, with their proposed generic naproxen/esomeprazole magnesium products. For immediate access to our complimentary reports, including today’s coverage, register for free now at: http://protraderdaily.com/register/.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ARLZ. Go directly to your stock of interest and access today’s free coverage at: http://protraderdaily.com/optin/?symbol=ARLZ.

The Announcement

This upholds of validity of the two patents follows the patent infringement lawsuits filed by an Aralez’s subsidiary on April 21, 2011, July 25, 2011, and June 28, 2013, in District Court against Dr. Reddy’s, Lupin, and Mylan, respectively, related to the Abbreviated New Drug Applications (ANDA) filed with the FDA to market generic versions of VIMOVO. The lawsuits filed denotes infringement claim of US Patent Nos. 8,557,285 (‘285 patent) and 6,926,907 (‘907 patent) titled “Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs,” which cover VIMOVO. The District Court’s decision was made based on the validity of the ‘285 and ‘907 patents for VIMOVO and the Court’s judgment will prevent Dr. Reddy’s, Mylan, and Lupin from launching generic versions of VIMOVO in the United States until at least the expiration of the relevant patent.

The Company views this announcement as a fair and appropriate ruling regarding the litigation. The Company stated that the ruling demonstrates the strength of its portfolio of VIMOVO and Yosprala, while it remains committed aggressively to defend its intellectual property portfolio.

What is VIMOVO?

VIMOVO is a fixed combination of naproxen, a non-steroidal anti-inflammatory drug, and esomeprazole, a proton pump inhibitor (PPI) indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. The drug decreases the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. The drug VIMOVO is not interchangeable with the individual components of naproxen and esomeprazole magnesium.

VIMOVO currently has 14 Orange Book listed patents with terms that exceed up to 20131. The ‘907 patent is also listed in the Orange Book for Yosprala (aspirin/omeprazole) and has been asserted against Teva Pharmaceuticals US, Inc., (NYSE: TEVA) in a separate patent infringement case.

Company Growth Prospects

Aralez recently announced on June 07, 2017, the national commercial launch of Zontivity (vorapaxar) in the US. Zontivity is the only antiplatelet therapy that inhibits PAR-1 mediated platelet aggregation in response to thrombin. Zontivity is a once-daily agent indicated for the reduction of thrombotic CV events in patients with a history of myocardial infarction in patients with the peripheral arterial disease. This announcement came on the heels of the commencement of phased launch of Zontivity on April 24, 2017, utilizing 15 sales representatives deployed to high volume physicians who treat post-MI and PAD patients.

On May 09, 2017, the Company announced its guidance as it expects net revenues to be in the range of $80 million to $100 million for the year ending December 31, 2017.

Last Close Stock Review

At the close of trading session on Wednesday, June 28, 2017, Aralez Pharma’s stock price rose 1.50% to end the day at $1.35. A total volume of 364.56 thousand shares were exchanged during the session. The Company’s shares advanced 8.00% in the last one month. At Wednesday’s closing price, the stock’s net capitalization stands at $83.54 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 467080